This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The hearing is scheduled to commence on Monday, December 2, 2024. The post DEA Administrator Announces Intent to Hold Hearings on Marijuana’s Scheduling appeared first on NORML.
For Immediate Release: August 28, 2024 Washington, D.C. — In light of the Drug Enforcement Administration’s (DEA) announcement to schedule a hearing on the rescheduling of cannabis, Americans for Safe Access (ASA) emphasizes the urgent need for compassionate leadership in Congress to advocate for the rights of medical cannabis patients.
What's Inside For September 2024: DEA Hearing Delay on Cannabis Rescheduling Patients caught in the middle of CA Hemp Product Ban ASA releases What’s in Your Cannabis? Is your membership Current? Learn More about ASA Member Benefits & Join Today! A Patient & Consumer Guide to Navigating Cannabis Safety.
Gavin Newsom in September 2024, which banned any detectable amount of THC in hemp products (including Delta-8 and Delta-9). In response to its growing popularity, the DEA announced in 2016 that kratom would be placed in the restrictive Schedule I along with cannabis. Yet its advocates tout its ability to help wean users off opioids.
For immediate release: Media Briefing on the Next Steps of the Rescheduling Process July 22, 2024, 1 pm ET Zoom Conference: Please go to the bottom of this page for the Zoom sign-in link.
Happy 2024 – let’s start the year off with a shout-out to Colorado, where the retail market is celebrating an anniversary. The DEA is conducting a review of cannabis scheduling. As of January 2024, 24 states have legalized adult-use cannabis; over half the US population lives in a state where it is legal.
The Drug Enforcement Administration (DEA) is working on amending the Farm Bill in 2024 to create new rules and regulations regarding synthetic weed. Since delta-8 is so unpopular in states with legal cannabis, the data suggests that it is often less appealing to consumers than actual weed.
Further, after several failed attempts to legalize medical cannabis, there’s is finally enough steam to put an initiative on the state’s 2024 ballot. Pro-medical cannabis lawmakers are preparing to introduce medical legalization to the state’s 2024 ballot. Sadly, the Nebraska Supreme Court struck down the initiative.
The DEA sends a letter to Georgia pharmacies. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it. But wait, isn’t there a provision that prohibits the Department of Justice (of which DEA is a part) from interfering with state legal medical marijuana programs?
It was called the “Cuban cigar of the marijuana world” by a DEA agent in 1967 and even compared with French wine. Healthcare expenditure estimated by 2024. Estimated Prevalence of cannabis users by 2024. It was a quite lucrative business, with a kilo worth 3$ at the farm easily sold for 4000$ in the U.S. in the 1970. Population.
With a recreational cannabis market geared up for launch on January 1, 2024, Virginians have a lot to look forward to. In fact, this year looks set to be one of the most successful years for cannabis reform in the United States so far. . billion by the fourth year of operation.
The 2019 edition of the Hemp and CBD Industry Factbook released figures that show retail sales of CBD topping $1 billion this year, and predicted that number could hit $10 billion by 2024. Circuit Court refuse to involve itself in the company’s fight with the DEA over cannabis research licenses.
one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. Watch Dr. Russo’s Presentation Hunter Land, Ph.D, the VP of Research & Development at Biopharmaceutical Research Company, Inc.,
As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. And finally, we arrive at December , when those Georgia pharmacies that made such a splash in October got a nastygram from the DEA. Watch for updates on this story in 2024.
The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. For obvious reasons, religious exemptions from the CSA do not present compelling opportunities for entrepreneurs. 2022 Active FDA Clinical Trials and State-Regulated Systems. View source.].
As a result, labs that have received a state license to test either medical or recreational cannabis have historically been denied a DEA Schedule I license to test hemp under the 2018 Farm Bill. However, this may change with rescheduling that is going to be revisited on Dec 2, 2024.
The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”
In case you haven’t heard, the Drug Enforcement Administration (DEA) wants to hear from you on marijuana rescheduling. Specifically, DEA invites your comments on its notice of proposed rulemaking (NPRM) to move both marijuana and marijuana extract from schedule I to schedule III of the federal Controlled Substances Act (CSA).
In a much anticipated announcement, the Drug Enforcement Administration (DEA) issued a notice of proposed rulemaking to reschedule marijuana, from Controlled Substances Act (CSA) schedule I to schedule III (the “Proposed Rule”). First , DEA is not proposing an interim final rule. 11, 2024) (“OLC Op.”).1 Levine, M.D.,
The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”
Diamondback Investment Group, LLC , handed the DEA a big loss when it comes to hemp – at least for now. In Anderson , the court held that DEA’s interpretation that a host of hemp-derived products were illegal was essentially wrong. Raimondo , a 2024 US Supreme Court decision. delta-9 THC. THC, it is legal.
The hemp industry is not the only one that’s pushing back against the Drug Enforcement Administration (DEA)’s hemp Interim Final Rule (the “ Rule ”). If you read this blog, you’ll recall the hemp industry sued the DEA following the release of its Rule in August 2020. billion by 2024, increasing from $1.2 billion in 2019.
In no particular order, I’ll address a few reasons why the back half of 2024 will be a bad stretch for intoxicating hemp products. Raimondo , a 2024 US Supreme Court decision. That’s because the DEA routinely issues what amount to opinion letters as to whether this or that cannabinoid is or is not a schedule I narcotic.
The hemp industry is not the only one that’s pushing back against the Drug Enforcement Administration (DEA)’s hemp Interim Final Rule (the “ Rule ”). If you read this blog, you’ll recall the hemp industry sued the DEA following the release of its Rule in August 2020. billion by 2024, increasing from $1.2 billion in 2019.
” As of a few days ago, DEA reiterated this position in response to an inquiry by attorney Shane Pennington, even going so far as to note “cannabis-derived THCA does not meet the definition of hemp under the [Controlled Substances Act] because upon conversion for identification purposes as required by Congress, it is equivalent to [THC].”
They’re calling it the Rural Prosperity and Food Security Act of 2024 (the “Senate bill”). The Senate bill follows on the House’s proposal, called the Farm, Food and National Security Act of 2024 (the “House bill”), offered in May. That could happen in 2024, but seems more likely in 2025 when the new Congress convenes.
Griffen’s article is just one of many parsing the language of the 2018 Farm Bill and a 2023 DEA letter on the topic. See also: “ THCA and the DEA: Rod Breaks Down the Latest News ” from Rod Kight, an another attorney prominent in the space. I would say: “Someone over at DEA wrote a letter last year indicating that it’s not.
Ability to source marijuana genetic material from outside Colorado Senate Bill 23-271 , which went into effect in early 2024, aims to enhance Colorados marijuana industry. In January 2022, the DEA issued a letter stating that cannabis seeds and other genetic material with 0.3% THC, then that material falls within CSA control.
Schedule III substances are subject to certain controls not applicable to all other prescription drugs, including the requirement that a medical professional with a specific license issued by the Drug Enforcement Agency (DEA) must conduct an in-person examination before prescribing it. What is treatment like at an in-person ketamine clinic?
Virginia 2024 adult use program may be postponed: [link]. DEA grants research license for psychedelics and major depression first human trial: [link]. Dallas County District Attorney discusses freeing up cops for 911 calls instead of 5 hours a piece on marijuana arrest paperwork: [link].
According to the Pew Research Center (2024), 88% of Americans believe cannabis should be legal for either medical or recreational use. If Congress would like to change the legal status of marijuana, they would do so before or after the DEA makes a final scheduling decision. What is 280E. New Frontier Data. Pew Research Center.
In the world of hemp, Senator Mitch McConnell has directed the DEA to figure out how to distinguish hemp from marijuana. ” Since the CBD industry is projected to surpass $20 billion by 2024 , those tests might come in handy. Note that McConnell still refers to marijuana as hemp’s “illicit cousin.”
Image by 7raysmarketing from Pixabay Lawmakers Frustrated with DEA Inaction Despite Guidance from President Biden and Department of Health and Human Services “It is time for the DEA to make good on the President’s commitments,” said the senators. Text of Letter (PDF) April 26, 2024 – Washington, D.C. – On Thursday, U.S.
Yesterday, the Drug Enforcement Administration (DEA) near-noticed a hearing for its marijuana rescheduling proposal. The hearing would begin on December 2, 2024 at 9 a.m. Back in March, when DEA agreed to initiate rulemaking to reschedule marijuana, I wrote that “I doubt cannabis will be on Schedule III by November.”
HHS DOCUMENT RELEASE Last month , the Department of Health and Human Services (HHS) released a heavily redacted version of their recommendation to the Drug Enforcement Administration (DEA) that cannabis be moved from Schedule I to Schedule III. Of course, the DEA will make its own decision, as we noted earlier this month.
cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Key global cannabis law developments in 2024 Germany passed a quasi-legalization law with two phases. As the U.S.
DE-SCHEDULING As we’re reported before (most recently here ), the Department of Health and Human Services (HHS) has recommended that the Drug Enforcement Administration (DEA) move cannabis from Schedule I to Schedule III. Now, some Senate Democrats are advocating that the DEA de-schedule cannabis altogether.
The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. Virginia also legalized cannabis in 2021, but residents can expect to wait until 2024 before they can purchase cannabis products. More States Favor Cannabis Legalization.
But there’s a group of players who’ve been surprisingly quiet, despite potentially having the most to gain: DEA-registered bulk marijuana manufacturers. However, under current US law, DEA Registrants are missing out on a massive opportunity. tons in Q4 of 2024 a fourfold increase from Q1. billion by 2027.
Drug Enforcement Administration (“DEA”), the agency tasked with enforcing the CSA. In principal at least, if the EB-5 cannabis investment is solely supplying cannabis to approved, licensed researchers pursuant to preexisting DEA approval then that is not “trafficking in an illicit substance” under the INA.
The official hearing with the DEA (Drug Enforcement Administration) to determine whether or not to move cannabis to Schedule III is slated for next month, and advocates are hopeful that the measure will pass. It is scheduled at the same level as heroin.”
UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. It seems likely that 2024 will bring a decision on re-scheduling, either for or against, so stay tuned for that. Look for more on this in 2024 also.
“Accordingly, no state has the jurisdiction to legalize recreational use of marijuana without Congressionally enacted reform or the Drug Enforcement Agency (DEA) taking administrative action to reschedule it,” he wrote. “As Bill To Go Into Effect In 2024. But other Democrats, including Sen.
They must work closely with the Drug Enforcement Administration (DEA) to pass the move. At the tail end of the Biden Administration, the process experienced setbacks when the DEA was accused of unfairly blocking pro-cannabis advocates from participating in rescheduling hearings and improperly communicating with anti-cannabis groups.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content